Evaluation of Risk Factors for Postbooster Omicron COVID-19 Deaths in England

Nafilyan, Vahé; Ward, Isobel; Robertson, Chris; Sheikh, Aziz

doi:10.1001/jamanetworkopen.2022.33446

Cited by 12 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…male gender was not found to be significantly connected with disease progression. While in our study and some other studies, 8,43,44 an increased risk was observed in male gender. Several studies have hypothesized that lower testosterone levels in elderly males and males with underlying diseases, as well as hormone differences in inflammatory processes between males and females, could explain these results 7,45 .…”

Section: Discussionsupporting

confidence: 52%

Clinical characteristics and factors for serious outcomes among outpatients infected with the Omicron subvariant BF.7

Yang,

Wang,

Zhang

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

To evaluate clinical characteristics and identify risk factors associated with severe outcomes in outpatients infected with the Omicron subvariant BF.7, data were collected from outpatients diagnosed with Corona Virus Disease 2019 from December 19, 2022 to January 5, 2023. Clinical characteristics were analyzed using descriptive statistics. Univariate and multivariate logistic regression analyses were conducted to identify factors associated with serious outcomes. Variables with a p < 0.10 in the univariate analysis were included in the multivariate model. Our study analyzed 770 patients, of whom 380 (49.4%) were male, with a median age of 59. The most common symptoms reported were cough (71.2%), fever (64.7%), and sore throat (37.7%). Fever lasted an average of 5.93 ± 3.37 days for the general population and 10.64 ± 7.12 days for impaired‐immunity patients. Most cases were mild (68.7%), followed by moderate (27.1%). Severe cases accounted for 2.2%, with 0.5% critically ill. Serious outcomes occurred in 4.2% of cases, with 11 deaths during follow‐up. Underlying‐diseases patients had a higher rate of serious outcomes. Factors associated with serious outcomes included receiving a three‐dose vaccination (odds ratio [OR] = 0.324, 95% confidence interval [CI]: 0.113–0.932, p = 0.037), male gender (OR = 2.890, 95% CI: 1.107–7.548, p = 0.030), age (OR = 1.060, 95% CI: 1.024–1.097, p = 0.001), and chest tightness or dyspnea at the time of visit (OR = 4.861, 95% CI: 2.054–11.507, p < 0.001). Our study found that cough, fever, and sore throat were the most common symptoms reported by patients. Receiving a three‐dose vaccination was protective, while male gender, age, and chest tightness or dyspnea were identified as risk factors for serious outcomes.

show abstract

Section: Discussionsupporting

confidence: 52%

Clinical characteristics and factors for serious outcomes among outpatients infected with the Omicron subvariant BF.7

Yang,

Wang,

Zhang

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…The odds ratio scores indicate the 60+ age (17.9; 95% CI 16.2–19.8), males (1.3; 95% CI 1.3–1.3), and presence of comorbidities (1.5; 95% CI 1.4–1.5) as potential risk factors. Finally, Nafilyan et al [ 62 ] collected integrated data from the Office for National Statistics Public Health Data Asset (England) to infer the risk factors for COVID-19 death after receiving a booster dose of vaccine during the Omicron wave. The mortality risk was still more strongly correlated with age than with other factors, such as being male and having comorbidities.…”

Section: Discussionmentioning

confidence: 99%

Risk Factors Associated with Mortality in Hospitalized Patients with COVID-19 during the Omicron Wave in Brazil

et al. 2022

View full text Add to dashboard Cite

Considering the imminence of new SARS-CoV-2 variants and COVID-19 vaccine availability, it is essential to understand the impact of the disease on the most vulnerable groups and those at risk of death from the disease. To this end, the odds ratio (OR) for mortality and hospitalization was calculated for different groups of patients by applying an adjusted logistic regression model based on the following variables of interest: gender, booster vaccination, age group, and comorbidity occurrence. A massive number of data were extracted and compiled from official Brazilian government resources, which include all reported cases of hospitalizations and deaths associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Brazil during the “wave” of the Omicron variant (BA.1 substrain). Males (1.242; 95% CI 1.196–1.290) aged 60–79 (3.348; 95% CI 3.050–3.674) and 80 years or older (5.453; 95% CI 4.966–5.989), and hospitalized patients with comorbidities (1.418; 95% CI 1.355–1.483), were more likely to die. There was a reduction in the risk of death (0.907; 95% CI 0.866–0.951) among patients who had received the third dose of the anti-SARS-CoV-2 vaccine (booster). Additionally, this big data investigation has found statistical evidence that vaccination can support mitigation plans concerning the current scenario of COVID-19 in Brazil since the Omicron variant and its substrains are now prevalent across the entire country.

show abstract

“…Moreover, data from well conducted randomized clinical or observational studies providing more specific information on patients who may benefit from therapy are urgently awaited. Specifically, data on the effects of that drugs on acute but also long-term risk reduction of most vulnerable but vaccinated/boostered people, specifically immuno-compromised patients and elderly people with multiple risk factors ( 12 ) would be important to guide and optimize therapy with those anti-viral drugs.…”

mentioning

confidence: 99%

Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely

Weiß

2023

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Evaluation of Risk Factors for Postbooster Omicron COVID-19 Deaths in England

Abstract: This cohort study of adults in England evaluates the association of sociodemographic and clinical risk factors with death from COVID-19 among individuals who completed primary vaccination and received a messenger RNA (mRNA) booster.

Cited by 12 publications

References 7 publications

Clinical characteristics and factors for serious outcomes among outpatients infected with the Omicron subvariant BF.7

Clinical characteristics and factors for serious outcomes among outpatients infected with the Omicron subvariant BF.7

Risk Factors Associated with Mortality in Hospitalized Patients with COVID-19 during the Omicron Wave in Brazil

Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely

Contact Info

Product

Resources

About